Jeffrey C. Goh
A5018801649- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- PARP inhibition in cancer therapy
- Ovarian cancer diagnosis and treatment
- Radiopharmaceutical Chemistry and Applications
- Renal and related cancers
- Pancreatic and Hepatic Oncology Research
- Bladder and Urothelial Cancer Treatments
- Cancer Genomics and Diagnostics
- Toxin Mechanisms and Immunotoxins
- Advancements in Semiconductor Devices and Circuit Design
- Economic and Financial Impacts of Cancer
- Cancer Treatment and Pharmacology
- Immunotherapy and Immune Responses
- Endometrial and Cervical Cancer Treatments
- Cancer, Lipids, and Metabolism
- BRCA gene mutations in cancer
- Cancer survivorship and care
- Immune Cell Function and Interaction
- Ferroptosis and cancer prognosis
- Radio Frequency Integrated Circuit Design
- Cancer Research and Treatments
- Prostate Cancer Diagnosis and Treatment
- Cytokine Signaling Pathways and Interactions
Royal Brisbane and Women's Hospital
2016-2025
Queensland University of Technology
2022-2025
The University of Queensland
2018-2024
Icon (Australia)
2023-2024
Holy Spirit Northside Private Hospital
2024
Gallipoli Medical Research Foundation
2022-2023
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
2020-2023
Queensland Health
2023
Cancer Care Services
2021
National Cancer Center Hospital East
2017
Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared that sunitinib is unclear.
The efficacy and safety of nivolumab plus cabozantinib as compared with those sunitinib in the treatment previously untreated advanced renal-cell carcinoma are not known.
Pembrolizumab has previously shown antitumor activity against programmed death ligand 1 (PD-L1)-positive metastatic castration-resistant prostate cancer (mCRPC). Here, we assessed the and safety of pembrolizumab in three parallel cohorts a larger mCRPC population.
There is an unmet need for therapeutic options that prolong survival patients with heavily pretreated, metastatic castration-resistant prostate cancer (mCRPC). The phase III, open-label KEYLYNK-010 study evaluated pembrolizumab plus olaparib versus a next-generation hormonal agent (NHA) biomarker-unselected, previously treated mCRPC.
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. trial updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. We present final prespecified overall survival (OS) analysis of open-label, phase III CLEAR study treatment-naïve...
5007 Background: Efficacy of PD-1 inhibition has not been demonstrated in large-scale mCRPC trials. Pembro showed preliminary antitumor activity PD-L1+ KEYNOTE-028 (n = 23). Here, we present results from cohorts 1-3 258) the phase 2 KEYNOTE-199 study pembro monotherapy docetaxel-refractory (NCT02787005). Methods: Cohorts 1 (C1) and (C2) enrolled patients (pts) with RECIST-measurable PD-L1– disease, respectively. C3 pts nonmeasurable, bone-predominant disease. All had ECOG PS 0-2 received ≥1...
308 Background: First-line NIVO+CABO met primary and secondary efficacy endpoints by improving progression-free survival (PFS; HR 0.51, P < 0.0001), overall (OS; 0.60, = 0.0010), objective response rate (ORR; 55.7% vs 27.1%; 0.0001) SUN in patients (pts) with aRCC CheckMate 9ER (Choueiri et al. ESMO 2020). Efficacy benefits were consistent across prespecified subgroups including IMDC risk group, regardless of tumor PD-L1 expression (database lock for analysis, March 30, Updated analyses...
5000 Background: We previously reported that in men with mCRPC progressing after docetaxel randomly assigned LuPSMA vs. cabazitaxel (Lancet 2021), those has significant improvements PSA response rate (66% 37%), RECIST (49% 24%), progression-free survival (HR 0.63), less G3-4 toxicities (33% 53%) and better patient-reported outcomes. now report the secondary endpoint of overall (OS) mature follow-up, for trial participants, also initially excluded because low PSMA-expression or discordant...
4502 Background: In the phase 3 CLEAR trial, L+P showed clinically meaningful and statistically significant benefits in PFS (primary endpoint) OS, improved ORR compared with S 1L aRCC (Motzer NEJM 2021). Here, we report 4-yr follow-up results from final prespecified OS analysis of (data cutoff: 31 Jul 2022). Methods: Treatment-naïve pts (n=1069) who had a clear-cell component were randomized (1:1:1) to receive: L 20 mg PO QD + P 200 IV Q3W; or 18 everolimus 5 QD; 50 (4 wks on/2 off)....
LBA358 Background: CheckMate 914 (NCT03138512) is a phase 3, randomized, double-blind, multicenter, 2-part trial evaluating adjuvant NIVO plus ipilimumab (NIVO+IPI) vs PBO (Part A) or monotherapy (and NIVO+IPI to assess the contribution of components; Part B) designed in sequence mutually exclusive patients (pts) with localized RCC at high risk post-nephrectomy relapse. Results from A 37.0 months median study follow-up (range, 15.4–58.0) showed no disease-free survival (DFS) benefit for...
5500 Background: LuPSMA is a radiolabeled small molecule that delivers therapeutic β-radiation to PSMA-expressing tumors. Encouraging efficacy and safety has been shown in non-randomized studies of mCRPC. TheraP randomized phase II trial comparing vs cabazitaxel men with mCRPC progressing after docetaxel. Methods: Men mCRPC, imaging 68 Ga-PSMA-11 18 F-FDG PET/CT confirmed high PSMA-expression no sites FDG-positive/PSMA-negative disease, were randomly assigned (1:1) (6-8GBq q6weeks up 6...
Introduction The phase 3 CLEAR study demonstrated that lenvatinib plus pembrolizumab significantly improved efficacy versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (RCC). Prognostic features including presence and/or site of baseline metastases, prior nephrectomy, and sarcomatoid have been associated disease success. This subsequent analysis explores outcomes in or without specific prognostic features. Methods In CLEAR, clear RCC were randomly...
TPS271 Background: Combination immune checkpoint inhibitors (ICI) with ipilimumab and nivolumab has been shown to induce adaptive responses in patients mCRPC, albeit resulting modest clinical benefit. There is growing evidence that radiation may enhance the activity of ICI by modulating tumour microenvironment. We hypothesize radionuclide 177 Lu-PSMA-617 result immunogenic cell death therefore synergise combination improve long term outcomes. EVOLUTION aims determine safety mCRPC. Methods:...
PURPOSE CheckMate 914 is a two-part, randomized phase III trial evaluating adjuvant nivolumab plus ipilimumab (part A) or monotherapy B) versus placebo in mutually exclusive populations of patients with localized renal cell carcinoma (RCC) at high risk postnephrectomy recurrence. Part A showed no disease-free survival (DFS) benefit for placebo. We report results from part B. METHODS Patients were randomly assigned (2:1:1) to (240 mg once every 2 weeks up 12 doses), placebo, doses) (1 mg/kg 6...
The standard treatment for endometrial cancer is hysterectomy with or without bilateral salpingo-oophorectomy; however, this may not be an optimal choice women who have completed childbearing are at a high risk of surgical complications. Conservative levonorgestrel intrauterine devices appear to effective in patients early-stage cancer; mismatch repair-deficient (dMMR) tumors low likelihood responding devices. To assess the efficacy dostarlimab, active immune checkpoint inhibitor that...